Search for Clinical Trial Results
Mucopolysaccharidoses - 25 Studies Found
Status | Study |
Completed |
Study Name: Phase I/II Study of Retroviral-Mediated Transfer of Iduronate-2-Sulfatase Gene Into Lymphocytes of Patients With Mucopolysaccharidosis II (Mild Hunter Syndrome) Condition: Mucopolysaccharidosis II Date: 1999-10-18 Interventions: Genetic: lymphocyte gene therapy |
Recruiting |
Study Name: Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI Condition:
|
Recruiting |
Study Name: A Treatment Study of Mucopolysaccharidosis Type IIIB Condition:
Date: 2016-02-27 Interventions: Drug: BMN 250 Chimeric fusion of recombinant human alpha-N-acetylglucosaminidase and truncated human ins |
Active, not recruiting |
Study Name: Longitudinal Study of Bone Disease in Children With Mucopolysaccharidoses (MPS) I, II, and VI Condition: Mucopolysaccharidoses Date: 2011-11-11 |
Completed |
Study Name: Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II) Condition: Mucopolysaccharidosis II Date: 2003-09-29 Interventions:
|
Recruiting |
Study Name: Natural History Study of Patients With MPS IIIA Condition: Mucopolysaccharidosis IIIA Date: 2016-04-15 |
No longer available |
Study Name: An Open-Label Treatment Protocol With UX003 rhGUS Enzyme Replacement Therapy for an Advanced Stage MPS 7 Patient Condition: Mucopolysaccharidosis Type 7 Date: 2014-03-24 Interventions: Drug: UX003 Open Label Other Names: |
Enrolling by invitation |
Study Name: Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I Condition: Mucopolysaccharidosis I Date: 2017-02-27 Interventions: Drug: AGT-181 Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion |
Active, not recruiting |
Study Name: Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I Condition: Mucopolysaccharidosis I Date: 2017-02-09 Interventions: Drug: AGT-181 Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion |
Recruiting |
Study Name: Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II Condition: Mucopolysaccharidosis II Date: 2017-01-13 Interventions: Biological: SB-913 Single dose of each of the 3 components of SB-913: ZFN1, ZFN2 and hIDS Donor |